Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Paul V. Viscuse; Mario L. Marques-Piubelli; Meghan M. Heberton; Edwin Roger Parra; Amishi Y. Shah; Arlene Siefker-Radtke; Jianjun Gao; Sangeeta Goswami; Doina Ivan; Jonathan L. Curry; Matthew T. Campbell

doi:10.3389/fonc.2021.621591

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Paul V. Viscuse, Mario L. Marques-Piubelli, Meghan M. Heberton, Edwin Roger Parra, Amishi Y. Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L. Curry, Matthew T. Campbell

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.

Original language	English (US)
Article number	621591
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.621591
State	Published - Mar 4 2021

Keywords

SJS/TEN
adverse (side) effects
bladder cancer
enfortumab vedotin
erythema multiform
urothelial cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2021.621591

Fingerprint

Dive into the research topics of 'Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction'. Together they form a unique fingerprint.

Cite this

Viscuse, P. V., Marques-Piubelli, M. L., Heberton, M. M., Parra, E. R., Shah, A. Y., Siefker-Radtke, A., Gao, J., Goswami, S., Ivan, D., Curry, J. L., & Campbell, M. T. (2021). Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Frontiers in Oncology, 11, Article 621591. https://doi.org/10.3389/fonc.2021.621591

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. / Viscuse, Paul V.; Marques-Piubelli, Mario L.; Heberton, Meghan M. et al.
In: Frontiers in Oncology, Vol. 11, 621591, 04.03.2021.

Research output: Contribution to journal › Article › peer-review

Viscuse, PV, Marques-Piubelli, ML, Heberton, MM, Parra, ER , Shah, AY , Siefker-Radtke, A , Gao, J , Goswami, S , Ivan, D , Curry, JL & Campbell, MT 2021, 'Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction', Frontiers in Oncology, vol. 11, 621591. https://doi.org/10.3389/fonc.2021.621591

Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER , Shah AY , Siefker-Radtke A et al. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Frontiers in Oncology. 2021 Mar 4;11:621591. doi: 10.3389/fonc.2021.621591

Viscuse, Paul V. ; Marques-Piubelli, Mario L. ; Heberton, Meghan M. et al. / Case Report : Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. In: Frontiers in Oncology. 2021 ; Vol. 11.

@article{5572dc4620bd4113be41e7afd3438e1a,

title = "Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction",

abstract = "Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.",

keywords = "SJS/TEN, adverse (side) effects, bladder cancer, enfortumab vedotin, erythema multiform, urothelial cancer",

author = "Viscuse, {Paul V.} and Marques-Piubelli, {Mario L.} and Heberton, {Meghan M.} and Parra, {Edwin Roger} and Shah, {Amishi Y.} and Arlene Siefker-Radtke and Jianjun Gao and Sangeeta Goswami and Doina Ivan and Curry, {Jonathan L.} and Campbell, {Matthew T.}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Viscuse, Marques-Piubelli, Heberton, Parra, Shah, Siefker-Radtke, Gao, Goswami, Ivan, Curry and Campbell.",

year = "2021",

month = mar,

day = "4",

doi = "10.3389/fonc.2021.621591",

language = "English (US)",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Case Report

T2 - Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

AU - Viscuse, Paul V.

AU - Marques-Piubelli, Mario L.

AU - Heberton, Meghan M.

AU - Parra, Edwin Roger

AU - Shah, Amishi Y.

AU - Siefker-Radtke, Arlene

AU - Gao, Jianjun

AU - Goswami, Sangeeta

AU - Ivan, Doina

AU - Curry, Jonathan L.

AU - Campbell, Matthew T.

PY - 2021/3/4

Y1 - 2021/3/4

N2 - Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.

AB - Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.

KW - SJS/TEN

KW - adverse (side) effects

KW - bladder cancer

KW - enfortumab vedotin

KW - erythema multiform

KW - urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85102885303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102885303&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.621591

DO - 10.3389/fonc.2021.621591

M3 - Article

C2 - 33747934

AN - SCOPUS:85102885303

SN - 2234-943X

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 621591

ER -

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this